Mineralys Therapeutics Ownership | Who Owns Mineralys Therapeutics?
Mineralys Therapeutics Ownership Summary
Mineralys Therapeutics is owned by 93.04% institutional investors, 2.52% insiders, and 4.44% retail investors.
MLYS Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Mineralys Therapeutics | 93.04% | 2.52% | 4.44% |
Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 109 | - | 46,482,607 | - | 93 | - | 109 | - | - | - |
Jun 30, 2024 | 95 | 1.06% | 44,151,037 | 5.44% | 89 | 1.03% | 61 | 45.24% | 14 | -57.58% |
Mar 31, 2024 | 94 | 6.82% | 41,871,729 | 20.62% | 93 | 1.01% | 42 | -27.59% | 33 | 120.00% |
Dec 31, 2023 | 88 | 14.29% | 34,713,391 | 30.93% | 95 | 2.31% | 58 | 16.00% | 15 | 36.36% |
Sep 30, 2023 | 77 | 13.24% | 26,512,068 | 5.26% | 64 | 1.70% | 50 | 19.05% | 11 | 22.22% |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Apr 01, 2025 | Rodman David Malcom | Chief Medical Officer | Sell | $458.54K |
Apr 01, 2025 | Rodman David Malcom | Chief Medical Officer | Sell | $375.75K |
Apr 01, 2025 | Rodman David Malcom | Chief Medical Officer | Sell | $44.72K |
Mar 13, 2025 | Samsara BioCapital GP, LLC | - | Buy | $8.10M |
Mar 13, 2025 | AKKARAJU SRINIVAS | - | Buy | $8.10M |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | 3 |
2025 Q1 | 3 | 3 |
2024 Q4 | - | 4 |
2024 Q3 | - | 4 |
2024 Q2 | - | 8 |
MLYS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools